<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8318">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02019004</url>
  </required_header>
  <id_info>
    <org_study_id>STU83962</org_study_id>
    <nct_id>NCT02019004</nct_id>
  </id_info>
  <brief_title>A Pilot Study Testing Onabotulinum Toxin A Versus Incobotulinum Toxin A Injections for Facial Wrinkles</brief_title>
  <official_title>Treatment of Forehead/Glabellar Rhytide Complex With Onabotulinum Toxin A Versus Incobotulinum Toxin A Injection: A Split-face, Double-blinded, Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the effectiveness of Botox® (Onabotulinum Toxin A)
      versus Xeomin® (incobotulinum toxin A) for the treatment of forehead and glabellar (vertical
      lines between the eyebrows) wrinkles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be screened, photographed, assessed, and randomized to be injected with
      onabotulinum toxin A on one side and incobotulinum toxin A on the other side during their
      first clinic visit. Subjects will return for a 2 week, 2 month, 3 month, 4 month, 5 month,
      and 6 month follow-up to have photographs taken by the unblinded research assistant at
      relaxed and full contraction.

      This study is a pilot study designed to determine feasibility of these procedures.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in glabellar wrinkle score from baseline to 6 months for botox vs. xeomin</measure>
    <time_frame>At baseline and at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two blinded dermatologists will rate each photograph of each subject at baseline and at month 6. The glabellar wrinkle rating is:
0: no facial wrinkles
mild facial wrinkles
moderate facial wrinkles
severe facial wrinkling</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in forehead wrinkle score from baseline to 6 months for botox vs. xeomin</measure>
    <time_frame>At baseline and at 6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Two blinded dermatologists will rate each photograph of each subject at baseline and at month 6. The forehead wrinkle Merz rating is:
0: no wrinkles
minimal wrinkles
mild wrinkles
moderate wrinkles
severe wrinkles</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Wrinkles</condition>
  <arm_group>
    <arm_group_label>Onabotulinum Toxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One side of the face will be randomized to receive Onabotulinum Toxin A injections in the forehead and glabellar region of the face.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Incobotulinum Toxin A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The other side of the face will be randomized to receive Incobotulinum Toxin A injections in the glabellar and forehead region of the face.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Onabotulinum Toxin A</intervention_name>
    <arm_group_label>Onabotulinum Toxin A</arm_group_label>
    <other_name>Botox</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Incobotulinum Toxin A</intervention_name>
    <arm_group_label>Incobotulinum Toxin A</arm_group_label>
    <other_name>Xeomin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females and males

          2. In good health

          3. Is 20-65 years of age

          4. Has static and moderate dynamic forehead/glabellar wrinkles

          5. Has willingness and the ability to understand and provide informed consent and
             communicate with the study staff

        Exclusion Criteria:

          1. Pregnant or lactating

          2. Younger than 20 or older than 65 years of age

          3. Has received the following treatments in the forehead or glabellar region:

               1. botulinum toxin injections in the past 6 months

               2. ablative laser procedure in the past 6 months

               3. radiofrequency device treatment in the past 6 months

               4. ultrasound device treatment in the past 6 months

               5. medium to deep chemical peel in the past 6 months

               6. temporary soft tissue augmentation material in the area to be treated in the
                  past year

               7. semi-permanent soft tissue augmentation material in the area to be treated in
                  the past 2 years

               8. permanent soft tissue augmentation material in the area to be treated

          4. Is planning to receive within the next 6 months, any cosmetic procedure (such as any
             chemical peels, botulinum toxin injections, ablative or non-ablative laser
             procedures, filler injections, radiofrequency procedures, dermabrasion, ultrasound
             and face lifting procedures) in the forehead or glabellar region.

          5. Is planning to use tretinoin or retinoic acid in the next 6 months

          6. Has an active infection in the forehead or glabellar region (excluding mild acne)

          7. Is allergic to cow's milk protein

          8. Is allergic to albumin

          9. Taking aminoglycoside

         10. Is currently using anticoagulation therapy

         11. Has a history of bleeding disorders

         12. Has a mental illness

         13. Unable to understand the protocol or to give informed consent
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murad Alam, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emily Poon, PhD</last_name>
    <phone>312-695-4761</phone>
    <email>research.nuderm@northwestern.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Northwestern University Department of Dermatology</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Poon, PhD</last_name>
      <phone>312-695-4761</phone>
      <email>research.nuderm@norhtwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Murad Alam, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 23, 2013</lastchanged_date>
  <firstreceived_date>November 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Murad Alam</investigator_full_name>
    <investigator_title>Professor in Dermatology, Otolaryngology - Head and Neck Surgery, and Surgery-Organ Transplantation</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
